,Performance Evaluation for In Vitro Diagnostic Medical Devices Overview
The EU IVDR 2017/746 defines Performance Evaluation for In Vitro Diagnostic Medical Devices (IVD) in article 2 as:
“an assessment and analysis of data to establish or verify the scientific validity, the analytical and, where applicable, the clinical performance of a device.”
The Performance Evaluation for In Vitro Diagnostic medical devices serves as a fundamental framework for performance evaluation. However, crafting the PEP can be quite intricate and demanding due to its critical role in demonstrating the device's safety, efficacy, and alignment with its intended use. To ensure the development of a well-established and high-quality document, it is essential to adhere to the detailed requirements laid out in Annex VIII of the EU IVDR 2017/746.
Designing your IVDR Performance Evaluation Plan (PEP) Template
To create an effective IVDR performance evaluation plan (PEP) template following points should be considered:
- Define Intended Use and Performance Characteristics The initial step involves meticulous determination and definition of the device's intended use. This should encompass specific disorders, conditions, or risk factors that the IVD device is designed to detect.
- Identify Performance Characteristics Once the intended use is established, the subsequent task is to identify the performance characteristics of the device. The PEP must include the basis of specifications used to assess the device's performance, covering parameters such as sensitivity, specificity, accuracy, trueness, repeatability, reproducibility, limits of detection, and quantitation for both analytical and clinical performance.
- Determine Clinical Evidence Requirements Based on the intended use and performance characteristics, an evaluation of the device's clinical evidence requirements must be conducted. This entails determining the type of clinical studies needed to effectively demonstrate the device's safety and performance.
- Outline Development Phases The PEP should provide a comprehensive overview of each development phase, including the sequence and methods used to assess scientific, analytical, and clinical performance. It is imperative to include a synopsis of key stages in the process and the potential acceptance criteria.
- Performance Evaluation Plan Updates As the study progresses and new information emerges, it may be necessary to update the PEP. This could involve revising study protocols, adjusting clinical evidence requirements, or modifying the Performance Evaluation Plan in its entirety to accommodate changes in the intended use or performance characteristics of the device.
By meticulously adhering to these steps and incorporating any updates based on study results, manufacturers can ensure a well-structured and effective performance evaluation plan, ultimately facilitating a robust performance evaluation of their IVD devices as mandated by the EU IVDR.
Freyr, a renowned provider of regulatory solutions, offers comprehensive support in Performance Evaluation Plan (PEP) services for medical writing. With the expertise in the EU IVDR 2017/746 and vast knowledge of regulatory requirements, Freyr assists in devising well-structured PEPs. From defining intended use to determining performance characteristics and clinical evidence requirements, Freyr ensures high-quality documentation to meet regulatory compliance.
Performance Evaluation for In Vitro Diagnostic Medical Devices
- Transition plan for IVDR compliance.
- Scientific validity reports based on literature and/or in-house data.
- Clinical performance reports based on literature and/or in-house data.
- Analytical Performance Reports.
- Clinical Evidence or Performance Evaluation Reports as per IVDR
- Performance Evaluation Plan (PEP) Template
- Post Market Performance Follow Up (PMPF) protocols and reports.
- Post Market Surveillance (PMSR) protocols and reports.
- Writing/Revising other documents, such as package insert/IFU, Quick Reference Instructions (QRI), operation/user manual, etc.
- Assured compliance with recent applicable regulations.
- Team of qualified experts.
- Tailored Solutions to your requirements
- Regulatory Resource Management/Staff Augmentation Services
- Cross-functional inputs from Medical Device experts to comply with requirements.
Frequently Asked Questions
01. What is a Performance Evaluation Plan (PEP) under EU IVDR?
A Performance Evaluation Plan (PEP) is a structured document outlining how an IVD manufacturer will generate, collect, and assess evidence to demonstrate scientific validity, analytical performance, and clinical performance. It translates intended purpose into measurable objectives, data sources, methodologies, and acceptance criteria that guide lifecycle evidence generation under IVDR.
02. Why is a Performance Evaluation Plan mandatory under IVDR?
The IVDR requires a documented, proactive strategy for performance evaluation to ensure evidence is systematic, traceable, and risk based. A PEP ensures manufacturers define how performance characteristics will be demonstrated before compiling reports, strengthening regulatory transparency and reducing gaps during Notified Body review.
03. What key elements must be included in a compliant PEP?
A compliant PEP defines intended purpose, performance characteristics, data sources, study designs, methodologies, statistical approaches, and acceptance criteria. It also explains how scientific validity, analytical, and clinical evidence will be identified and evaluated, ensuring alignment with General Safety and Performance Requirements.
04. How does intended purpose influence the Performance Evaluation Plan?
Intended purpose drives the entire PEP. It determines which performance characteristics are relevant, what populations and specimen types must be studied, and which endpoints are meaningful. A clearly articulated intended purpose reduces ambiguity and ensures the evidence strategy remains scientifically and regulatorily coherent.
05. When should manufacturers develop a Performance Evaluation Plan?
The PEP should be created early in product development, ideally during design planning. Early definition of evidence needs allows appropriate study design, literature strategy, and resource allocation, preventing delays and inconsistencies later when preparing the Performance Evaluation Report and technical documentation.
06. How does a PEP support lifecycle compliance?
A PEP is not static; it should evolve as new evidence, design changes, or post-market data emerge. By defining update triggers and evidence monitoring strategies, the PEP becomes a living framework that supports continuous performance evaluation and long-term IVDR compliance.
07. What are common gaps identified in Performance Evaluation Plans?
Common gaps include vague intended purpose statements, unclear justification of performance characteristics, weak acceptance criteria, and insufficient linkage between risk classification and evidence strategy. Notified Bodies often question PEPs that lack traceability between claims, methods, and planned data sources.
08. Why is Freyr considered a leading partner for IVDR Performance Evaluation Plan services?
Leading PEP partners combine regulatory insight, analytical and clinical expertise, and structured documentation practices to ensure alignment across intended purpose, claims, and evidence planning. Freyr’s integrated IVDR approach and experience across scientific validity, analytical, and clinical pillars position it as a trusted partner for robust, Notified Body-ready Performance Evaluation Plans.
